Skip to main content
Premium Trial:

Request an Annual Quote

Roche Sales Up 1 Percent for First Nine Months of 2010, Dx Biz up 8 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche today announced an 8 percent sales growth in its diagnostics division during the first nine months of the year, while company-wide sales rose 1 percent.

For the nine months ended Sept. 30, the Swiss pharmaceutical, diagnostics, and research products firm said that its diagnostics business increased to CHF7.7 billion ($8.1 billion), up from CHF7.4 billion ($7.7billion). Within the division, molecular diagnostics rose 4 percent in local currencies to CHF900 million, while applied science diagnostics grew 8 percent to CHF646 million.

Tissue diagnostics rose 18 percent to CHF393 million.

Company-wide sales for the nine months were CHF36.13 billion, compared to CHF36.40 billion in the year-ago period, a 2 percent increase in local currencies.

Pharmaceutical sales rose 1 percent in local currencies to CHF28.40 billion from CHF29.03 billion in the first nine months of 2009.

For its third quarter ended Sept.30, Roche's total sales slid 7 percent to CHF11.49 billion from CHF12.29 billion in Q3 2009. The diagnostics business rose less than 1 percent to CHF2.48 billion from CHF2.46 billion a year ago.

Roche's microarray business, housed in the applied science segment within diagnostics, increased 22 percent, helped along by the launch of NimbleGen's SeqCap Exome target enrichment technology for next-generation sequencing.

Sales of MagNA Pure and LightCycler products for sample preparation and PCR analysis were flat "due mainly to decreasing demand for influenza A (H1N1) virus testing," Roche said in a statement.

In molecular diagnostics, the company said that growth was driven by virology and blood screening in Eastern Europe, North America, and Asia-Pacific. Roche said also that strong demand continued for its cobas 4800 system in parts of Europe, Latin America, and Asia-Pacific.

In a conference call accompanying the release of its earnings, Daniel O'Day, COO of the diagnostics division, said that Roche's GS Junior System, a smaller next-generation sequencing platform from Roche company 454 Life Sciences that is being rolled out, is seeing "good uptake."

For full-year 2010, the company said it expects mid single-digit sales growth company wide, while the diagnostics business is expected to grow "significantly" ahead of the market.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.